Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | 4WHIM study: safety & efficacy of mavorixafor in patients with WHIM syndrome

David Dale • 10 Jun 2022
EHA 2022
Rare Diseases Mavorixafor
4WHIM

David Dale, MD, University of Washington, Seattle, WA, comments on 4WHIM, a Phase II trial that investigates the use of mavorixafor (NCT03005327), an antagonist to the receptor whose mutation causes WHIM disease. This experimental approach seeks to replace the current treatment based on antibiotics and cytokines. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from David Dale

Diagnosis and treatment of neutropenia
0:46
Diagnosis and treatment of neutropenia
David Dale • 10 Jun 2022
An overview of the biology of WHIM syndrome
0:31
An overview of the biology of WHIM syndrome
David Dale • 10 Jun 2022

Related Videos

Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
3:04
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals